Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial

BACKGROUND: Advanced colorectal cancer is treated with a combination of cytotoxic drugs and targeted treatments. However, how best to minimise the time spent taking cytotoxic drugs and whether molecular selection can refine this further is unknown. The primary aim of this study was to establish how...

Descripción completa

Detalles Bibliográficos
Autores principales: Wasan, Harpreet, Meade, Angela M, Adams, Richard, Wilson, Richard, Pugh, Cheryl, Fisher, David, Sydes, Benjamin, Madi, Ayman, Sizer, Bruce, Lowdell, Charles, Middleton, Gary, Butler, Rachel, Kaplan, Richard, Maughan, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012566/
https://www.ncbi.nlm.nih.gov/pubmed/24703531
http://dx.doi.org/10.1016/S1470-2045(14)70106-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012566/
https://www.ncbi.nlm.nih.gov/pubmed/24703531
http://dx.doi.org/10.1016/S1470-2045(14)70106-8

Ejemplares similares